Application of low dose remifentanil combined with midazolam conscious sedation in Gastroscopy of obese patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048241

Enrollment

Unknown

Registered

2021-07-05

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:Midazolam

Control group:Propofol

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18-65 years old, BMI >= 28kg/m^2, gender is not limited; 2. ASA classification: I-II level; 3. Visit a doctor because of gastrointestinal symptoms and voluntarily accept painless gastroscopy; 4. Normal cognitive function.

Exclusion criteria

Exclusion criteria: 1. Patients with acute respiratory infection within the past 2 weeks; 2. Patients with severe insufficiency of the heart, liver, lung, kidney and other important organs; 3. There are contraindications to gastroscopy; 4. Patients with neuropsychiatric diseases; 5. Allergic constitution or allergic to the research drug; 6. Oral, nasal or throat infection or tumor; 7. A history of difficult tracheal intubation anesthesia and severe sleep apnea syndrome.

Design outcomes

Primary

Measure	Time frame
Incidence of hypoxia;	—

Secondary

Measure	Time frame
Success rate of sedation;Patient satisfaction;Satisfaction of endoscopists;	—

Countries

China

Contacts

Public ContactZou Yinghua

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

zou.yinghua@163.com+86 18930170153

Outcome results